| Literature DB >> 31406252 |
Yiran Liang1, Xiaojin Song1, Yaming Li1, Peng Su2, Dianwen Han1, Tingting Ma1, Renbo Guo3, Bing Chen4, Wenjing Zhao4, Yuting Sang1, Ning Zhang1, Xiaoyan Li1, Hanwen Zhang1, Ying Liu1, Yi Duan1, Lijuan Wang4, Qifeng Yang5,6.
Abstract
Increasing evidence has indicated that circular RNAs (circRNAs) play a critical role in cancer development. However, only a small number of circRNAs have been experimentally validated and functionally annotated. In this study, using a high-throughput microarray assay, we identified a novel circRNA, circKDM4C, which was downregulated in breast cancer tissues with metastasis. Furthermore, we analyzed a cohort of breast cancer patients and found that circKDM4C expression was decreased in breast cancer tissues, and lower circKDM4C expression was associated with poor prognosis and metastasis in breast cancer. Functionally, we demonstrated that circKDM4C significantly repressed breast cancer proliferation, metastasis, and doxorubicin resistance in vitro and in vivo. Mechanistically, using a dual-luciferase activity assay and AGO2 RNA immunoprecipitation, circKDM4C was identified as a miR-548p sponge. We also found that PBLD was a direct target of miR-548p, which functioned as a tumor suppressor in breast cancer. Moreover, miR-548p overexpression was able to reverse the circKDM4C-induced attenuation of malignant phenotypes and elevated expression of PBLD in breast cancer cells. Taken together, our data indicate that circKDM4C might have considerable potential as a prognostic biomarker in breast cancer, and support the notion that therapeutic targeting of circKDM4C/miR-548p/PBLD axis may be a promising treatment approach for breast cancer patients.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31406252 DOI: 10.1038/s41388-019-0926-z
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867